Table 1 Clinical characteristics of recruited subjects. Data is presented as mean (±SEM).

From: Role of DNA-LL37 complexes in the activation of plasmacytoid dendritic cells and monocytes in subjects with type 1 diabetes

Characteristic

T1D

HC

Patients (n)

55

25

Age (years)

12.9 ± 0.55

19.78 ± 1.47

Sex (M/F)

31/24

16/9

Fasting plasma C-peptide (ng/mL)*

0.43 ± 0.05

2.61 ± 0.29

HbA1c (%)*

11.04 ± 0.37

5.21 ± 0.07

Anti-insulin antibodies (% subjects)

16/55 (29%)

0/25 (0%)

Anti-IA-2 antibodies (% subjects)

23/55 (42%)

0/25 (0%)

Anti-GAD65 antibodies (% subjects)

38/55 (69%)

1/25 (4%)

Triple antibody positive (% subjects)

10/55 (18%)

0/25 (0%)

Double antibody positive (GAD65 and IA-2, % subjects)

11/55 (20%)

0/25 (0%)

Double antibody positive (GAD65 and Insulin, % subjects)

6/55 (11%)

0/25 (0%)

Double antibody positive (IA-2 and Insulin, % subjects)

3/55 (5%)

0/25 (0%)

  1. M/F, Male/female; HbA1c, Glycated haemoglobin; GAD, Glutamic acid decarboxylase; IA-2, Islet antigen 2.
  2. * p < 0.01, T1D versus HC. Unpaired t-test was used to compare means between different groups.
  3. The minimum detectable levels (with intra, inter-assay CV) for anti-insulin was 0.5 U/mL (3.1, 5.1%), anti-GAD65, 0.57 u/mL (6.4, 5.8%) and anti-IA-2, 0.95 u/mL (2.0, 4.3%).
Back to article page